StockData
Viatris Inc logo

Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3010% below fair value
$20.82+0.15 (+0.73%)

Close on Nov 13, 2026Market cap $23.91BP/E –Yield 2.31%

Viatris Inc grew revenue 4.3% to $14.73B over the twelve months to Sep 30, 2026. Free cash flow was $2.11B, up 27.1% from a year earlier. At the latest close the market valued the company at $23.91B.

Revenue
$14.73B
+4.3% vs. a year earlier
Operating income
-$4.60M
TTM Q3 2026
Free cash flow
$2.11B
+27.1% vs. a year earlier
EPS, diluted
-$3.00
FY2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$23.91B
P/E ratio
–
Price to sales
1.62
Price to book
–
Dividend yield
2.31%
Free cash flow yield
8.83%

Fundamentals

Revenue
$14.73B
EPS, diluted
-$3.00
Free cash flow
$2.11B
Diluted shares
1.15B

Trading

Next earnings
Feb 25, 2027 (estimated, before the open)
Previous close
$20.67
Open
$20.77
Day's range
$20.39 – $20.86
Volume
6,514,717
Average volume (20 days)
9,559,105
Index membership
S&P 500 (since Dec 2020), Russell 1000 (since Dec 2020), Russell 3000 (since Nov 2020)
Beta (5 years)
0.86
52-week range
$10.15 – $21.20
RSI (14 days)
70.1
Volatility (1 year)
30.8%
Relative volume
0.70×
WACC
7.5%

On 1 of our idea list: Superinvestor favorites

Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodVTRSS&P 500DifferenceVTRS per yearS&P 500 per year
1 month+20.7%-3.0%+23.7 pts
3 months+30.8%-2.8%+33.6 pts
Year to date+71.2%+11.5%+59.7 pts
1 year+97.6%+13.5%+84.1 pts
3 years+163.9%+77.7%+86.2 pts+38.2%+21.1%
5 years+82.1%+72.6%+9.5 pts+12.7%+11.5%
10 years-31.3%+308.2%−339.4 pts-3.7%+15.1%

Nine years at a glance

Fiscal years 2017 to 2025 and trailing twelve months, USD

Revenue

$14.73B+4.3% YoY

Gross profit

$5.20B+2.3% YoY

Operating income

-$4.60M

EPS, diluted

–

Free cash flow

$2.11B+27.1% YoY
Reported periodTrailing twelve months

Press releases

Releases Viatris filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Viatris

Pharmaceutical Preparations

Viatris Inc. is a global healthcare company that provides pharmaceutical treatments across more than ten major therapeutic categories, including cardiovascular health, oncology, and infectious diseases. Its portfolio comprises generic medications, complex formulations, established iconic brands, and innovative therapies. The company operates through four commercial segments: Developed Markets, Emerging Markets, JANZ, and Greater China. Its primary customers include retail and pharmacy establishments, pharmaceutical wholesalers and distributors, governments, insurers, and healthcare institutions like hospitals.

Company profile, executives and history

Viatris stock: common questions

What is Viatris's stock price?

VTRS closed at $20.82 on Nov 13, 2026, up 0.73% on the day. Over the past 52 weeks it traded between $10.15 and $21.20.

What is Viatris's market cap?

Viatris was worth $23.91B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is VTRS's P/E ratio?

Viatris lost money over fiscal 2025 (diluted EPS -$3.00), so it has no meaningful P/E ratio.

How much revenue does Viatris make?

Viatris reported revenue of $14.73B for the twelve months to Sep 30, 2026, up 4.3% from a year earlier.

Does Viatris pay a dividend?

Yes. Viatris paid $0.48 per share over the last twelve months, a yield of 2.31% at the latest price.

When does Viatris report earnings next?

Viatris is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has VTRS stock performed over the past year?

Including dividends, VTRS returned +97.6% over the past year, against +13.5% for the S&P 500.

How many VTRS shares are sold short?

35M shares were sold short at the latest FINRA report, 3.08% of the float, or 4.0 days of average trading volume.

Who are Viatris's competitors?

Companies most similar to Viatris by business, industry and size include TEVA, GRFS, BHC, OGN, ZTS.

See a number that looks wrong?